Study of IgG and IgM antibody response afterPfizer mRNA Vaccine first dose in Previously infected with COVID-19and uninfected individuals
NeuroQuantology
; 20(8):7591-7595, 2022.
Article
in English
| EMBASE | ID: covidwho-2010532
ABSTRACT
The current research aimedto demonstrate the extent such as increase in the rate of immune response to antibodies (IgG, IgM) for people who received the first dose of the Pfizer mRNA vaccine at (1-3) weeks times period and to compare them with people who were not taken for the first dose of the same vaccine and none infected with COVID-19.Also the results appearedsignificant variations in immunoglobulin (IgG) levels (P≤ 0.05) between case (Recipients mRNA vaccination) and control patients, there were. In terms of age and gender, however, there were no significant changes (P≥ 0.05) in immunoglobulin (IgM) levels between case (Recipients mRNA vaccination) and control patients.
adult; antibody response; article; controlled study; coronavirus disease 2019; drug therapy; female; gender; gene expression; human; immune response; immunoglobulin blood level; male; vaccination; endogenous compound; immunoglobulin G; immunoglobulin G antibody; immunoglobulin M; immunoglobulin M antibody; messenger RNA; RNA vaccine
Full text:
Available
Collection:
Databases of international organizations
Database:
EMBASE
Topics:
Vaccines
Language:
English
Journal:
NeuroQuantology
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS